HEADER TRANSCRIPTION 30-APR-08 2ZNQ TITLE HUMAN PPAR DELTA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC TITLE 2 AGONIST TIPP401 COMPND MOL_ID: 1; COMPND 2 MOLECULE: PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: LIGAND BINDING DOMAIN; COMPND 5 SYNONYM: PPAR-DELTA, PPAR-BETA, NUCLEAR RECEPTOR SUBFAMILY 1 GROUP C COMPND 6 MEMBER 2, NUCLEAR HORMONE RECEPTOR 1, NUC1, NUCI; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: PPARD, NR1C2, PPARB; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 511693; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PET28A KEYWDS NUCLEAR RECEPTOR, PROTEIN-LIGAND COMPLEX, PPAR, ACTIVATOR, DNA- KEYWDS 2 BINDING, METAL-BINDING, NUCLEUS, RECEPTOR, TRANSCRIPTION, KEYWDS 3 TRANSCRIPTION REGULATION, ZINC-FINGER EXPDTA X-RAY DIFFRACTION AUTHOR T.OYAMA,Y.HIRAKAWA,N.NAGASAWA,H.MIYACHI,K.MORIKAWA REVDAT 6 01-NOV-23 2ZNQ 1 HETSYN REVDAT 5 29-JUL-20 2ZNQ 1 COMPND REMARK SEQADV HETNAM REVDAT 5 2 1 SITE REVDAT 4 02-MAR-16 2ZNQ 1 TITLE REVDAT 3 11-APR-12 2ZNQ 1 JRNL VERSN REVDAT 2 28-JUL-09 2ZNQ 1 JRNL REVDAT 1 05-MAY-09 2ZNQ 0 JRNL AUTH T.OYAMA,K.TOYOTA,T.WAKU,Y.HIRAKAWA,N.NAGASAWA,J.KASUGA, JRNL AUTH 2 Y.HASHIMOTO,H.MIYACHI,K.MORIKAWA JRNL TITL ADAPTABILITY AND SELECTIVITY OF HUMAN PEROXISOME JRNL TITL 2 PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) PAN AGONISTS REVEALED JRNL TITL 3 FROM CRYSTAL STRUCTURES JRNL REF ACTA CRYSTALLOGR.,SECT.D V. 65 786 2009 JRNL REFN ISSN 0907-4449 JRNL PMID 19622862 JRNL DOI 10.1107/S0907444909015935 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH K.OHKANE,J.KASUGA,T.OYAMA,Y.HIRAKAWA,K.MORIKAWA,M.MAKISHIMA, REMARK 1 AUTH 2 Y.HASHIMOTO,H.MIYACHI REMARK 1 TITL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) AGONISTS REMARK 1 TITL 2 WITH A 3,4-DIHYDRO-2H-BENZO[E][1,3]OXAZINE AND REMARK 1 TITL 3 2,3,4,5-TETRAHYDROBENZO[F][1,4]OXAZEPINE SKELETON: EFFECTS REMARK 1 TITL 4 OF THE CONFORMATIONAL RESTRICTION ON PPAR AGONISTIC ACIVITY REMARK 1 REF TO BE PUBLISHED REMARK 1 REFN REMARK 1 REFERENCE 2 REMARK 1 AUTH J.KASUGA,T.OYAMA,Y.HIRAKAWA,M.MAKISHIMA,K.MORIKAWA, REMARK 1 AUTH 2 Y.HASHIMOTO,H.MIYACHI REMARK 1 TITL IMPROVEMENT OF THE TRANSACTIVATION ACTIVITY OF REMARK 1 TITL 2 PHENYLPROPANOIC ACID-TYPE PEROXISOME PROLIFERATOR-ACITVATED REMARK 1 TITL 3 RECTPROR PAN AGONISTS; EFFECT OF INTRODUCTION OF FLUORINE AT REMARK 1 TITL 4 THE LINKER PART REMARK 1 REF TO BE PUBLISHED REMARK 1 REFN REMARK 2 REMARK 2 RESOLUTION. 2.65 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 1.1 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.65 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 42.35 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 99107.780 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 94.5 REMARK 3 NUMBER OF REFLECTIONS : 18668 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.214 REMARK 3 FREE R VALUE : 0.276 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.900 REMARK 3 FREE R VALUE TEST SET COUNT : 910 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.009 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.65 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.82 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 79.80 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2511 REMARK 3 BIN R VALUE (WORKING SET) : 0.2650 REMARK 3 BIN FREE R VALUE : 0.3210 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.50 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 119 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.029 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4214 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 98 REMARK 3 SOLVENT ATOMS : 83 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 31.60 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 31.70 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 1.86000 REMARK 3 B22 (A**2) : 10.84000 REMARK 3 B33 (A**2) : -12.70000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 4.30000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.31 REMARK 3 ESD FROM SIGMAA (A) : 0.33 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.42 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.43 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.008 REMARK 3 BOND ANGLES (DEGREES) : 1.300 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 19.70 REMARK 3 IMPROPER ANGLES (DEGREES) : 1.240 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.090 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 1.830 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 1.570 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 2.440 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.35 REMARK 3 BSOL : 30.57 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : WATER.PARAM REMARK 3 PARAMETER FILE 3 : B7G_XPLOR_PARAM.TXT REMARK 3 PARAMETER FILE 4 : 401_PARAM.TXT REMARK 3 PARAMETER FILE 5 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : WATER.TOP REMARK 3 TOPOLOGY FILE 3 : B7G_XPLOR_TOP.TXT REMARK 3 TOPOLOGY FILE 4 : 401_TOP.TXT REMARK 3 TOPOLOGY FILE 5 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2ZNQ COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBJ ON 12-MAY-08. REMARK 100 THE DEPOSITION ID IS D_1000028198. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 01-FEB-08 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 9.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SPRING-8 REMARK 200 BEAMLINE : BL38B1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0000 REMARK 200 MONOCHROMATOR : FIXED EXIT SI 111 DOUBLE CRYSTAL REMARK 200 MONOCHROMATOR REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : RIGAKU JUPITER 210 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 19488 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.650 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.0 REMARK 200 DATA REDUNDANCY : 3.700 REMARK 200 R MERGE (I) : 0.09300 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 8.6000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.65 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.74 REMARK 200 COMPLETENESS FOR SHELL (%) : 93.3 REMARK 200 DATA REDUNDANCY IN SHELL : 3.10 REMARK 200 R MERGE FOR SHELL (I) : 0.28200 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: CNS REMARK 200 STARTING MODEL: PDB ENTRY 2B50 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 54.87 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.73 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 14% PEG8000, 200MM KCL, 40MM BISTRIS REMARK 280 ETHANE, 6% PROPANEDIOL, 0.5% N-HEPTYL-BETA-D-GLUCOPYRANOSIDE, REMARK 280 1MM EDTA, 1MM CACL2 , PH 9.5, VAPOR DIFFUSION, HANGING DROP, REMARK 280 TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 45.97350 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2, 3 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 3 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 202 REMARK 465 SER A 203 REMARK 465 HIS A 204 REMARK 465 MET A 205 REMARK 465 PRO A 206 REMARK 465 GLN A 207 REMARK 465 VAL A 208 REMARK 465 ALA A 209 REMARK 465 LYS A 265 REMARK 465 GLN A 266 REMARK 465 LEU A 267 REMARK 465 VAL A 268 REMARK 465 ASN A 269 REMARK 465 GLY A 270 REMARK 465 GLY B 202 REMARK 465 SER B 203 REMARK 465 HIS B 204 REMARK 465 LYS B 240 REMARK 465 ALA B 241 REMARK 465 SER B 242 REMARK 465 HIS B 243 REMARK 465 THR B 244 REMARK 465 LYS B 265 REMARK 465 GLN B 266 REMARK 465 LEU B 267 REMARK 465 VAL B 268 REMARK 465 ASN B 269 REMARK 465 GLY B 270 REMARK 465 MET B 476 REMARK 465 TYR B 477 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LYS A 240 134.21 -37.51 REMARK 500 SER A 242 -5.20 -58.21 REMARK 500 LYS A 260 -98.32 -70.74 REMARK 500 LEU A 262 -85.73 23.26 REMARK 500 VAL A 263 -74.78 -84.95 REMARK 500 ALA A 342 71.28 45.80 REMARK 500 LYS A 358 -67.21 -4.88 REMARK 500 GLU A 378 48.51 35.40 REMARK 500 ASP A 396 41.27 -106.56 REMARK 500 ALA A 428 90.38 -64.35 REMARK 500 GLU A 460 49.43 -95.97 REMARK 500 THR A 461 -19.86 -45.50 REMARK 500 HIS B 250 -6.66 -140.07 REMARK 500 LEU B 262 -16.94 -43.88 REMARK 500 VAL B 263 -72.07 -146.59 REMARK 500 LYS B 275 -56.09 -143.21 REMARK 500 ALA B 342 72.65 45.55 REMARK 500 ASN B 343 22.68 49.29 REMARK 500 ASN B 402 68.98 -108.42 REMARK 500 GLN B 429 -82.64 -31.97 REMARK 500 GLU B 460 59.63 -107.44 REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2ZNN RELATED DB: PDB REMARK 900 AN ISOFORM PROTEIN COMPLEXED WITH A RELATED LIGAND REMARK 900 RELATED ID: 2ZNO RELATED DB: PDB REMARK 900 AN ISOFORM PROTEIN COMPLEXED WITH A RELATED LIGAND REMARK 900 RELATED ID: 2ZNP RELATED DB: PDB REMARK 900 THE SAME PROTEIN COMPLEXED WITH A RELATED LIGAND DBREF 2ZNQ A 206 477 UNP Q03181 PPARD_HUMAN 170 441 DBREF 2ZNQ B 206 477 UNP Q03181 PPARD_HUMAN 170 441 SEQADV 2ZNQ GLY A 202 UNP Q03181 EXPRESSION TAG SEQADV 2ZNQ SER A 203 UNP Q03181 EXPRESSION TAG SEQADV 2ZNQ HIS A 204 UNP Q03181 EXPRESSION TAG SEQADV 2ZNQ MET A 205 UNP Q03181 EXPRESSION TAG SEQADV 2ZNQ GLY B 202 UNP Q03181 EXPRESSION TAG SEQADV 2ZNQ SER B 203 UNP Q03181 EXPRESSION TAG SEQADV 2ZNQ HIS B 204 UNP Q03181 EXPRESSION TAG SEQADV 2ZNQ MET B 205 UNP Q03181 EXPRESSION TAG SEQRES 1 A 276 GLY SER HIS MET PRO GLN VAL ALA ASP LEU LYS ALA PHE SEQRES 2 A 276 SER LYS HIS ILE TYR ASN ALA TYR LEU LYS ASN PHE ASN SEQRES 3 A 276 MET THR LYS LYS LYS ALA ARG SER ILE LEU THR GLY LYS SEQRES 4 A 276 ALA SER HIS THR ALA PRO PHE VAL ILE HIS ASP ILE GLU SEQRES 5 A 276 THR LEU TRP GLN ALA GLU LYS GLY LEU VAL TRP LYS GLN SEQRES 6 A 276 LEU VAL ASN GLY LEU PRO PRO TYR LYS GLU ILE SER VAL SEQRES 7 A 276 HIS VAL PHE TYR ARG CYS GLN CYS THR THR VAL GLU THR SEQRES 8 A 276 VAL ARG GLU LEU THR GLU PHE ALA LYS SER ILE PRO SER SEQRES 9 A 276 PHE SER SER LEU PHE LEU ASN ASP GLN VAL THR LEU LEU SEQRES 10 A 276 LYS TYR GLY VAL HIS GLU ALA ILE PHE ALA MET LEU ALA SEQRES 11 A 276 SER ILE VAL ASN LYS ASP GLY LEU LEU VAL ALA ASN GLY SEQRES 12 A 276 SER GLY PHE VAL THR ARG GLU PHE LEU ARG SER LEU ARG SEQRES 13 A 276 LYS PRO PHE SER ASP ILE ILE GLU PRO LYS PHE GLU PHE SEQRES 14 A 276 ALA VAL LYS PHE ASN ALA LEU GLU LEU ASP ASP SER ASP SEQRES 15 A 276 LEU ALA LEU PHE ILE ALA ALA ILE ILE LEU CYS GLY ASP SEQRES 16 A 276 ARG PRO GLY LEU MET ASN VAL PRO ARG VAL GLU ALA ILE SEQRES 17 A 276 GLN ASP THR ILE LEU ARG ALA LEU GLU PHE HIS LEU GLN SEQRES 18 A 276 ALA ASN HIS PRO ASP ALA GLN TYR LEU PHE PRO LYS LEU SEQRES 19 A 276 LEU GLN LYS MET ALA ASP LEU ARG GLN LEU VAL THR GLU SEQRES 20 A 276 HIS ALA GLN MET MET GLN ARG ILE LYS LYS THR GLU THR SEQRES 21 A 276 GLU THR SER LEU HIS PRO LEU LEU GLN GLU ILE TYR LYS SEQRES 22 A 276 ASP MET TYR SEQRES 1 B 276 GLY SER HIS MET PRO GLN VAL ALA ASP LEU LYS ALA PHE SEQRES 2 B 276 SER LYS HIS ILE TYR ASN ALA TYR LEU LYS ASN PHE ASN SEQRES 3 B 276 MET THR LYS LYS LYS ALA ARG SER ILE LEU THR GLY LYS SEQRES 4 B 276 ALA SER HIS THR ALA PRO PHE VAL ILE HIS ASP ILE GLU SEQRES 5 B 276 THR LEU TRP GLN ALA GLU LYS GLY LEU VAL TRP LYS GLN SEQRES 6 B 276 LEU VAL ASN GLY LEU PRO PRO TYR LYS GLU ILE SER VAL SEQRES 7 B 276 HIS VAL PHE TYR ARG CYS GLN CYS THR THR VAL GLU THR SEQRES 8 B 276 VAL ARG GLU LEU THR GLU PHE ALA LYS SER ILE PRO SER SEQRES 9 B 276 PHE SER SER LEU PHE LEU ASN ASP GLN VAL THR LEU LEU SEQRES 10 B 276 LYS TYR GLY VAL HIS GLU ALA ILE PHE ALA MET LEU ALA SEQRES 11 B 276 SER ILE VAL ASN LYS ASP GLY LEU LEU VAL ALA ASN GLY SEQRES 12 B 276 SER GLY PHE VAL THR ARG GLU PHE LEU ARG SER LEU ARG SEQRES 13 B 276 LYS PRO PHE SER ASP ILE ILE GLU PRO LYS PHE GLU PHE SEQRES 14 B 276 ALA VAL LYS PHE ASN ALA LEU GLU LEU ASP ASP SER ASP SEQRES 15 B 276 LEU ALA LEU PHE ILE ALA ALA ILE ILE LEU CYS GLY ASP SEQRES 16 B 276 ARG PRO GLY LEU MET ASN VAL PRO ARG VAL GLU ALA ILE SEQRES 17 B 276 GLN ASP THR ILE LEU ARG ALA LEU GLU PHE HIS LEU GLN SEQRES 18 B 276 ALA ASN HIS PRO ASP ALA GLN TYR LEU PHE PRO LYS LEU SEQRES 19 B 276 LEU GLN LYS MET ALA ASP LEU ARG GLN LEU VAL THR GLU SEQRES 20 B 276 HIS ALA GLN MET MET GLN ARG ILE LYS LYS THR GLU THR SEQRES 21 B 276 GLU THR SER LEU HIS PRO LEU LEU GLN GLU ILE TYR LYS SEQRES 22 B 276 ASP MET TYR HET B7G A 921 19 HET 401 A 922 30 HET B7G B 920 19 HET 401 B 923 30 HETNAM B7G HEPTYL BETA-D-GLUCOPYRANOSIDE HETNAM 401 (2S)-2-{3-[({[2-FLUORO-4-(TRIFLUOROMETHYL) HETNAM 2 401 PHENYL]CARBONYL}AMINO)METHYL]-4-METHOXYBENZYL}BUTANOIC HETNAM 3 401 ACID HETSYN B7G HEPTYL-BETA-D-GLUCOPYRANOSIDE; HEPTYL BETA-D-GLUCOSIDE; HETSYN 2 B7G HEPTYL D-GLUCOSIDE; HEPTYL GLUCOSIDE HETSYN 401 (S)-2-{3-[(2-FLUORO-4-TRIFLUOROMETHYLBENZOYLAMINO) HETSYN 2 401 METHYL]-4-METHOXYBENZYL} BUTYRIC ACID FORMUL 3 B7G 2(C13 H26 O6) FORMUL 4 401 2(C21 H21 F4 N O4) FORMUL 7 HOH *83(H2 O) HELIX 1 1 ASP A 210 PHE A 226 1 17 HELIX 2 2 THR A 229 GLY A 239 1 11 HELIX 3 3 ASP A 251 LYS A 260 1 10 HELIX 4 4 GLU A 276 SER A 302 1 27 HELIX 5 5 ILE A 303 SER A 308 1 6 HELIX 6 6 PHE A 310 ALA A 331 1 22 HELIX 7 7 ARG A 350 SER A 355 1 6 HELIX 8 8 ARG A 357 ASP A 362 1 6 HELIX 9 9 ILE A 364 ASN A 375 1 12 HELIX 10 10 ALA A 376 GLU A 378 5 3 HELIX 11 11 ASP A 380 LEU A 393 1 14 HELIX 12 12 ASN A 402 HIS A 425 1 24 HELIX 13 13 TYR A 430 GLU A 460 1 31 HELIX 14 14 HIS A 466 LYS A 474 1 9 HELIX 15 15 MET B 205 LYS B 224 1 20 HELIX 16 16 THR B 229 LEU B 237 1 9 HELIX 17 17 ASP B 251 GLY B 261 1 11 HELIX 18 18 GLU B 276 SER B 302 1 27 HELIX 19 19 ILE B 303 SER B 308 1 6 HELIX 20 20 PHE B 310 ALA B 331 1 22 HELIX 21 21 ALA B 342 GLY B 344 5 3 HELIX 22 22 ARG B 350 SER B 355 1 6 HELIX 23 23 ARG B 357 ASP B 362 1 6 HELIX 24 24 ILE B 364 ALA B 376 1 13 HELIX 25 25 ASP B 380 LEU B 393 1 14 HELIX 26 26 ASN B 402 HIS B 425 1 24 HELIX 27 27 TYR B 430 GLU B 460 1 31 HELIX 28 28 HIS B 466 LYS B 474 1 9 SHEET 1 A 4 PHE A 247 ILE A 249 0 SHEET 2 A 4 GLY A 346 THR A 349 1 O PHE A 347 N PHE A 247 SHEET 3 A 4 GLY A 338 VAL A 341 -1 N LEU A 339 O VAL A 348 SHEET 4 A 4 VAL A 334 ASN A 335 -1 N ASN A 335 O GLY A 338 SHEET 1 B 4 PHE B 247 ILE B 249 0 SHEET 2 B 4 GLY B 346 THR B 349 1 O PHE B 347 N ILE B 249 SHEET 3 B 4 GLY B 338 VAL B 341 -1 N LEU B 339 O VAL B 348 SHEET 4 B 4 VAL B 334 ASN B 335 -1 N ASN B 335 O GLY B 338 CRYST1 39.172 91.947 96.361 90.00 98.01 90.00 P 1 21 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.025528 0.000000 0.003591 0.00000 SCALE2 0.000000 0.010876 0.000000 0.00000 SCALE3 0.000000 0.000000 0.010480 0.00000